Literature DB >> 19693752

[Follow-up at 24 months after treatment of overactive bladder with 0.2 % sodium chondroitin sulfate].

Annett Gauruder-Burmester1, G Popken.   

Abstract

AIM: A retrospective study was performed to investigate whether the improvement of symptoms achieved with 0.2 % sodium chondroitin sulfate in treating overactive bladder (OAB) persists after 24 months.
MATERIALS AND METHODS: Two years ago, a total of 82 patients with chronic OAB were randomly assigned to receive either anticholinergic treatment (Tolterodin; group A, n = 41) or 0.2 % sodium chondroitin sulfate (Gepan instill; group B, n = 41). Diagnostic assessment included a gynecological examination and history, urodynamic test-ing, introital ultrasound, and cystoscopy. Duration of treatment was 12 months. The patients underwent repeat follow-up after 24 months and the findings were compared with the results at 12 months.
RESULTS: In group A, 15 / 35 (43 %) women reported an improvement of symptoms after 12 months as opposed to only 5 / 35 (14 %) after 24 months. In group B, there was an improvement in 23 / 32 (72 %) at 12 months and in 18 / 32 (56 %) after 24 months (p = 0.001). The subjective results were corroborated by means of urodynamic test-ing, pad counts, voiding frequency and nycturia (voiding diary).
CONCLUSION: Our findings suggest that instillation treatment with 0.2 % sodium chondroitin sulfate results in a more sustained improvement or cure of the symptoms of overactive bladder due to development of a glycosaminoglycan layer. Long-term results are needed for confirmation. Georg Thieme Verlag Stuttgart * New York.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19693752     DOI: 10.1055/s-0029-1224600

Source DB:  PubMed          Journal:  Aktuelle Urol        ISSN: 0001-7868            Impact factor:   0.658


  6 in total

1.  The overlap of interstitial cystitis/painful bladder syndrome and overactive bladder.

Authors:  Maurice K Chung; Charles W Butrick; Cherie W Chung
Journal:  JSLS       Date:  2010-04-21       Impact factor: 2.172

2.  New aspects in the differential diagnosis and therapy of bladder pain syndrome/interstitial cystitis.

Authors:  Jochen Neuhaus; Thilo Schwalenberg; Lars-Christian Horn; Henry Alexander; Jens-Uwe Stolzenburg
Journal:  Adv Urol       Date:  2011-10-19

3.  Intravesical Glycosaminoglycan Replacement with Chondroitin Sulphate (Gepan(®) instill) in Patients with Chronic Radiotherapy- or Chemotherapy-Associated Cystitis.

Authors:  Thilo Schwalenberg; Frank Peter Berger; Lars Christian Horn; Phuc Ho Thi; Jens-Uwe Stolzenburg; Jochen Neuhaus
Journal:  Clin Drug Investig       Date:  2015-08       Impact factor: 2.859

4.  Intravesical Sodium Chondroitin Sulphate to Treat Overactive Bladder: Preliminary Result.

Authors:  Lokman Irkilata; Mustafa Aydin; Hasan Riza Aydin; Hüseyin Cihan Demirel; Mustafa Kadihasanoglu; Mustafa Kemal Atilla
Journal:  Int Neurourol J       Date:  2015-06-29       Impact factor: 2.835

5.  A prospective randomized controlled multicentre trial comparing intravesical DMSO and chondroïtin sulphate 2% for painful bladder syndrome/interstitial cystitis.

Authors:  Manuela Tutolo; Enrico Ammirati; Giulia Castagna; Katrien Klockaerts; Hendrik Plancke; Dieter Ost; Frank Van der Aa; Dirk De Ridder
Journal:  Int Braz J Urol       Date:  2017 Jan-Feb       Impact factor: 1.541

Review 6.  A systematic review and meta-analysis on the efficacy of intravesical therapy for bladder pain syndrome/interstitial cystitis.

Authors:  Jayanta M Barua; Ignacio Arance; Javier C Angulo; Claus R Riedl
Journal:  Int Urogynecol J       Date:  2015-11-20       Impact factor: 2.894

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.